CSWM
NKTR icon

Cassady Schiller Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Cassady Schiller Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 423
2021
Q4 		$0 Buy
+1
New +$217 ﹤0.01% 616

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Cassady Schiller Wealth Management's NKTR Position: Q1 2022 in Review

Cassady Schiller Wealth Management sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 1 share.

Cassady Schiller Wealth Management first reported a position in NKTR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

  • Cassady Schiller Wealth Management reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cassady Schiller Wealth Management sold 1 Nektar Therapeutics share in Q1 2022.
  • Cassady Schiller Wealth Management first reported a position in Nektar Therapeutics in Q4 2021 and held it in 1 quarter.
  • Cassady Schiller Wealth Management's Nektar Therapeutics position peaked at $0 in Q4 2021.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Cassady Schiller Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.